BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →

Loading INVA charts…

Search ticker or company⌘K

INVA

01Multicharts 02Comparables 03Price target

May we use analytics cookies to see how vpside is used, including anonymous session recordings? Accepting also loads the price chart, which sets its own cookies. Essential cookies are always on. Privacy

INVA · Innoviva, Inc. fundamentals · vpside

vpside

⌘K

INVAMarket cap $1.6B/Last filing 10-Q, Q2 FY26 · 5 Aug 2026/INVAMarket cap $1.6B/Last filing 10-Q, Q2 FY26 · 5 Aug 2026/INVAMarket cap $1.6B/Last filing 10-Q, Q2 FY26 · 5 Aug 2026/INVAMarket cap $1.6B/Last filing 10-Q, Q2 FY26 · 5 Aug 2026/

Filings synced 13:22 · Prices: prior close 30 Oct

INVA

Innoviva, Inc.

Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

01Multicharts 02Comparables 03Price target

Add a metric37 metrics

Revenue, quarterly

$120M+19.3% year on year

$150M$100M$50M$0

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 5 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

72.2%−10.9 pp year on year

85%80%75%70%

vpside.com

Q4 ’24Q2 ’25Q3 ’25Q1 ’26Q2 ’26

Company filings · 10-Q filed 5 Aug 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$570M+43.5% year on year

$750M$500M$250M$0

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 5 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

$189M−5.4% year on year

$400M$200M$0

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 5 Aug 2026 · TTM = last four quartersvpside.com

Chart 05 is empty

Chart 06 is empty

Fundamentals: company filings · Q4 = full year − nine months · TTM = last four quarters